1615. Efficacy of Long-Acting Cabotegravir and Rilpivirine in a Diverse Group of Patients in a Real-World Setting

BACKGROUND: Cabotegravir (CAB) + rilpivirine (RPV) is the first recommended complete long-acting (LA) regimen for maintenance of HIV-1 virologic suppression. The efficacy and safety of switching to CAB + RPV LA (CAR) has been shown in clinical trials. CAR injections offer less frequent dosing and ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Yared, Nicholas F, Gudipati, Smitha, Payne, Shannon, Alvi, Rija B R, Cherian, John, Lodivico, John Di, Markowitz, Norman, Brar, Indira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677126/
http://dx.doi.org/10.1093/ofid/ofad500.1450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677126/
http://dx.doi.org/10.1093/ofid/ofad500.1450

Ejemplares similares